Highly pathogenic avian influenza viruses pose a continuing global threat. Current vaccines will not protect against newly evolved pandemic viruses. The creation of 'universal' vaccines has been unsuccessful because the immunological mechanisms that promote heterosubtypic immunity are incompletely defined. We found here that rapamycin, an immunosuppressive drug that inhibits the kinase mTOR, promoted cross-strain protection against lethal infection with influenza virus of various subtypes when administered during immunization with influenza virus subtype H3N2. Rapamycin reduced the formation of germinal centers and inhibited class switching in B cells, which yielded a unique repertoire of antibodies that mediated heterosubtypic protection. Our data established a requirement for the mTORC1 complex in B cell class switching and demonstrated that rapamycin skewed the antibody response away from high-affinity variant epitopes and targeted more conserved elements of hemagglutinin. Our findings have implications for the design of a vaccine against influenza virus.
Influenza A viruses infect a broad range of avian and mammalian species, cause high rates of morbidity and mortality, and kill over 250,000 people each year. The emergence of highly pathogenic H5N1 avian strains of influenza virus poses a serious threat for a deadly pandemic 1 . Such viruses are endemic in poultry in Asia, Europe and Africa. The reported 59% mortality rate for the 637 humans confirmed as being infected with influenza virus H5N1 gives obvious cause for concern (http://www.who.int/influenza/human_animal_interface/ EN_GIP_20130829CumulativeNumberH5N1cases.pdf). Thus far, the H5N1 influenza viruses have not transmitted efficiently between people. However, influenza viruses change constantly, and as few as five mutations in an avian H5N1 virus enabled its aerosol transmission in ferrets 2, 3 . Ferrets are generally considered a surrogate for spreading among humans, and thus this result indicates that virulent variants of influenza virus H5N1 could emerge and cause a severe pandemic.
Vaccination is the most effective strategy for controlling the spread of influenza virus; however, the current vaccines have several limitations 4 . Most notably, the existing vaccines do not provide strong heterosubtypic immunity, which is defined as protection against multiple subtypes of influenza virus. Those virus subtypes are based on expression of the highly variable surface proteins hemagglutinin (HA) and neuraminidase (NA). Pressure from the host immune response drives the selection of HA and NA mutants that escape neutralization. Consequently, the current vaccines do not protect against continuously emerging strains that present as variants of circulating 'seasonal' viruses. Moreover, the existing vaccines do not protect against pandemic viruses that arise from the reassortment of gene segments between different strains of influenza virus, which leads to the emergence of HA and NA subtypes that have not been encountered before in human populations. Despite extensive surveillance for influenza viruses by both humans and animals, it is difficult to predict which variants of HA and NA might acquire epidemic or pandemic potential.
Another limitation of the current vaccines is that they are made in embryonated hen eggs. Production can be greatly limited if highly pathogenic strains are lethal to chick embryos, which occurs with some avian influenza virus H5N1 strains 4 . Even when production is straightforward, the process from virus isolation to product availability generally requires at least 6 months, a delay that could cost millions of lives in the event of a new pandemic caused by these rapidly spreading pathogens.
A 'universal' vaccine that induces immunity to conserved epitopes expressed in multiple subtypes of influenza A virus could protect against newly emerging strains, including highly virulent pandemic strains 4 . However, the immunological mechanisms that underlie the generation of such cross-reactive, heterosubtypic immune responses are poorly characterized, and attempts to generate broadly protective vaccines have had very limited success thus far 4 . Most epitopes conserved between different subtypes of influenza are from components internal to the virus, which limits their access for antibody neutralization. However, both CD8 + T cells and CD4 + T cells contribute to viral clearance by recognizing peptides derived from internal proteins of influenza virus 5 . While virus-specific memory T cells do not prevent the entry of virus into epithelial cells in the same manner that neutralizing antibodies do, such cells decrease influenza virus-related morbidity and mortality by eliminating infected cells and accelerating viral clearance. Moreover, after considerable effort, cross-reactive antibodies specific for HA epitopes conserved between different influenza subtypes have been identified [6] [7] [8] [9] [10] [11] [12] [13] . However, such 'broad-spectrum' B cell clones are extremely rare. Thus, a means for boosting the responses of memory T cells and B cells after vaccination against influenza virus merits extensive investigation, as it may enhance protection against newly emerging viruses that have the potential to create deadly pandemics.
Several groups have demonstrated that inhibiting the serine-threonine kinase mTOR by treatment with rapamycin enhances the generation of memory CD8 + T cells. mTOR responds to changes in the cellular environment and in turn regulates the survival, metabolism and proliferation of cells 14 . Given that rapamycin is an immunosuppressive drug that blocks the proliferation and migration of B cells and T cells, it is unexpected that rapamycin also enhances the generation of memory CD8 + T cells. That was first demonstrated after infection of mice with lymphocytic choriomeningitis virus or Listeria monocytogenes 15, 16 . Subsequently, rapamycin was shown to increase the abundance and quality of memory T cells after the infection of nonhuman primates with vaccinia virus 17 , the priming of mice with a heat shock protein-based cancer vaccine 18 or in vitro stimulation of T cells with peptide and antigen-presenting cells 19 . Rapamycin increases both the number of memory CD8 + T cells and the proportion with a long-lived memory phenotype (CD127 hi CD62L hi Bcl-2 hi KLRG1 lo ). However, it is not clear whether that enhanced memory generation improves protection after a secondary infection. In addition, whether an enhanced immune response will protect against a lethal heterosubtypic infection with influenza virus without exacerbating immunopathology and mortality remains unresolved.
We found here that treatment with rapamycin during primary infection with influenza virus subtype H3N2 protected mice against a lethal, heterosubtypic, secondary infection with influenza virus subtype H5N1, H7N9 or H1N1. Consequently, we used this system to investigate the components of the immune response critical for such protection. Unexpectedly, we found that CD8 + memory T cells were not required for such protection, although CD4 + T cells and B cells were essential. Rapamycin treatment reduced class switching in B cells and altered the pattern of immunoglobulin G (IgG) and IgM specificities, which yielded a unique antibody repertoire. In addition, transfer of serum was sufficient to protect naive mice against a lethal infection with influenza virus subtype H5N1. Together our data suggested that mTOR promoted class switching on B cells to generate a repertoire of high-affinity, class-switched antibodies that protected against subsequent infection with the same virus while reducing the frequency of antibodies potentially cross-reactive to conserved epitopes. Thus, current attempts to enhance immunity to conserved epitopes of universal vaccines may actually decrease the frequency of cross-reactive antibodies and hence reduce their capacity for heterosubtypic protection.
RESULTS

Rapamycin protects against lethal infection with H5N1
To investigate whether treatment with a low dose of rapamycin would enhance the efficacy of vaccination against a pathogenic strain of influenza virus of a different subtype, we infected mice intraperitoneally with 1 × 10 8 EID 50 (50% egg-infective dose) influenza A virus strain A/HK/x31 (HKx31, an H3N2 subtype; called 'HKx31' here) and treated them with rapamycin at a dose of 75 µg per kg body weight daily for 28 d beginning 1 d before infection ( Supplementary  Fig. 1 ). When given intraperitoneally, HKx31 undergoes a defective growth cycle and produces the full spectrum of viral proteins but no infectious virus, similar to a vaccine 20, 21 . After 28 d, we then infected mice intranasally with 4.5 × 10 5 EID 50 influenza virus strain ∆Vn1203 (H5N1; called '∆Vn1203' here), a recombinant virus that expresses the internal genes of influenza virus strain A/Puerto Rico/8/34 (called 'PR8' here) and the surface H5 and N1 glycoproteins from the virulent influenza virus strain A/Vietnam/1203/04. In addition, we modified the polybasic cleavage site in H5 of ∆Vn1203 to restrict cleavage to trypsin-like proteases and allow its use in a biosafety level 2 facility. This engineered ∆Vn1203 causes death at relatively low doses in mice 22 . Notably, daily treatment with rapamycin during primary infection with HKx31 resulted in a much greater proportion of mice that survived secondary infection with ∆Vn1203 than did daily treatment with PBS (Fig. 1a) . Mice given rapamycin lost less weight (Fig. 1b) and cleared virus faster (Fig. 1c) than did the PBS-treated control mice. Thus, treatment with rapamycin during virus priming enhanced protection against a lethal, heterosubtypic infection with influenza virus.
Because HKx31 undergoes a defective growth cycle when administered intraperitoneally, it elicits an immune response similar to that elicited by a vaccine. Nevertheless, we also investigated whether rapamycin would protect mice after intranasal infection with a live attenuated influenza virus that models intranasally administered vaccines such as FluMist. We treated mice with rapamycin 1 d before infecting them intranasally with a temperature-sensitive strain of influenza virus strain A/Hong Kong/1/68 at a dose of 1 × 10 6 TCID 50 (half-maximal tissue culture infectious dose) 23 . We continued the rapamycin treatment for 28 d, at which time we challenged the mice A r t i c l e s with ∆Vn1203. Mice treated with rapamycin lost less weight after challenge with ∆Vn1203 than did mice given PBS ( Supplementary  Fig. 2 ). Together these data demonstrated that rapamycin enhanced protection against a lethal infection with ∆Vn1203 when administered during a primary intranasal infection with live attenuated influenza virus or intraperitoneal infection with influenza virus of a different subtype.
Rapamycin protects against various influenza virus subtypes
We next investigated whether treatment with rapamycin would also protect mice against a lethal infection with other subtypes of influenza virus. We infected mice intraperitoneally with HKx31, treated them with rapamycin daily and challenged them intranasally with either influenza virus strain A/Anhui/1/2013 (a newly identified isolate of influenza virus subtype H7N9 obtained from a patient during an outbreak of influenza in China in 2013; called 'H7N9' here) [24] [25] [26] or PR8 (a strain of influenza virus subtype H1N1). Notably, mice infected with HKx31 and treated with rapamycin exhibited significantly better survival rates after infection with H7N9 or PR8 than did their counterparts treated with PBS ( Fig. 2) . Mice that received rapamycin also lost less weight than did their PBS-treated counterparts after infection with H7N9 ( Supplementary Fig. 3a) . Thus, protection mediated by treatment with rapamycin during primary infection with influenza virus was not limited to the H5N1 subtype but extended to influenza viruses of at least three different subtypes. Moreover, H7N9 does not contain the same internal genes as the laboratory strains, which makes this protection even more noteworthy.
Rapamycin-mediated protection requires viral priming
To determine whether a primary infection was required for the rapamycin-mediated protection against a lethal secondary infection, we treated mice with rapamycin for 28 d and infected them with ∆Vn1203 in the absence of a primary infection. We found that treatment with rapamycin without concurrent exposure to HKx31 left mice fully susceptible to the lethal infection with ∆Vn1203 ( Fig. 3a and Supplementary Fig. 3c ), which suggested that rapamycin provided protection by modulating the primary immune response. To confirm that rapamycin did not alter the ability of influenza virus to infect or replicate in epithelial cells, we analyzed viral titers in the lungs daily after infection with ∆Vn1203 in the presence of rapamycin. Lung titers immediately after infection with ∆Vn1203 were similar for rapamycin-and PBS-treated unprimed mice (Fig. 3b) , which indicated that rapamycin did not directly limit viral entry or replication.
To determine whether the rapamycin-mediated protection was antigen specific, we infected mice with HKx31, treated them daily with PBS or rapamycin and challenged them with Sendai virus, a parainfluenza virus type 1 that does not share substantial homology with influenza A virus. As a control, we also assessed mice that we treated with PBS or rapamycin but did not infect with HKx31 before infecting them with Sendai virus. Mice treated with either PBS or rapamycin, regardless of prior infection with HKx31, were not protected from lethal infection with Sendai virus (Fig. 3c and Supplementary  Fig. 3d ). Together these data confirmed the proposal that the protection provided by rapamycin was due to antigen-specific alterations in the primary immune response to HKx31.
CD8 + T cells are dispensable for protection
Given that treatment with rapamycin increases the number and quality of memory CD8 + T cells in other models of infection [15] [16] [17] [18] [19] , we investigated whether rapamycin enhanced influenza virus-specific CD8 + T cell memory. We infected mice with HKx31 and treated them for 27 d with PBS or rapamycin. At this time, we obtained a sample of blood from each mouse and quantified influenza virus-specific T cells by analysis of tetramer binding. Treatment with rapamycin resulted in a significantly larger number of memory CD8 + T cells specific for an epitope of influenza A virus nucleoprotein (amino acids 366-374) or acid polymerase (amino acids 224-233) presented by H-2D b than did treatment with PBS (Fig. 4a) . Furthermore, a greater proportion of T cells specific for either of those epitopes had a memory precursor CD127 hi KLRG1 lo phenotype in mice treated with rapamycin than in mice treated with PBS ( Supplementary Fig. 4) . Moreover, 5 d after secondary infection with ∆Vn1203, the number of influenza virus-specific T cells in the spleen and bronchoalveolar lavage fluid was higher in rapamycin-treated mice than in their PBS-treated counterparts (Fig. 4b) . These data showed that, similar to infection with lymphocytic choriomeningitis virus or L. monocytogenes, rapamycin increased the number and quality of memory CD8 + T cells after infection with influenza virus. To determine whether the increase in influenza virus-specific memory CD8 + T cells was responsible for the enhanced protection, we immunized mice with a genetically modified HKx31 virus that lacks the five dominant epitopes recognized by influenza virus-specific CD8 + T cells and therefore does not induce substantial populations of effector or memory CD8 + T cells (∆CD8-HKx31) 27 . We infected mice intraperitoneally with ∆CD8-HKx31, treated them for 28 d with PBS or rapamycin and then challenged them intranasally with ∆Vn1203. Before infecting the mice with ∆Vn1203, we analyzed a blood sample from each mouse to confirm that infection with ∆CD8-HKx31 did not generate memory CD8 + T cells specific for the major epitopes of influenza virus nucleoprotein or acid polymerase presented by H-2D b (noted above) or two epitopes presented by H-2K b : polymerase B (amino acids 703-711) or PB1-F2 (polymerase B of an alternative reading frame; amino acids 62-70) (data not shown). In the absence of detectable CD8 + memory T cells, treatment with rapamycin after infection with ∆CD8-HKx31 still protected mice against a lethal challenge with ∆Vn1203 ( Fig. 4c and Supplementary Fig. 3e ). This suggested that memory CD8 + T cells were not required for the rapamycin-mediated protection. As infection with ∆CD8-HKx31 may have generated memory CD8 + T cells specific for other viral epitopes not detected with those tetramers, we confirmed the lack of requirement for memory CD8 + T cells by depleting mice of memory CD8 + T cells. For this, we treated mice with antibody to CD8 (anti-CD8; clone 53-6.7) 1 d and 3 d before infection with HKx31 and 1, 3, 5 and 17 d after infection with HKx31. We also treated the mice with PBS or rapamycin beginning 1 d before infection with HKx31 and then daily for 28 d and then infected them with ∆Vn1203. Analysis of blood obtained just before infection with ∆Vn1203 showed that treatment with anti-CD8 effectively decreased the number of memory CD8 + T cells to an amount similar to that in a naive mouse ( Supplementary  Fig. 5a,b) . Again, in the absence of detectable memory CD8 + T cells, treatment with rapamycin after infection with HKx31 enhanced protection against a lethal infection with ∆Vn1203 (Fig. 4d) . Together these data demonstrated that although rapamycin increased the number and quality of memory CD8 + T cells, those memory cells were not required for the enhanced protection provided by rapamycin.
Protection requires CD4 + T cells
Given that CD8 + T cells did not mediate the heterosubtypic protection noted above, we determined whether CD4 + T cells were involved by depleting mice of CD4 + T cells by treating them with anti-CD4 (clone GK1. Fig. 5a and Supplementary  Fig. 3g ). To further determine whether CD4 + T cells were required during the primary infection versus during the secondary infection, we depleted mice of CD4 + T cells either during the early phase of the primary response (days −3, −1, +2, and +5 relative to infection with HKx31 on day 0) or just before secondary infection (days +22 and +24). Eliminating the CD4 + T cells just before the secondary infection did not diminish the rapamycin-mediated protection ( Fig. 5b  and Supplementary Fig. 3h ). In contrast, depletion during the early phase of the primary response completely abolished such protection ( Fig. 5c and Supplementary Fig. 3i ). These data showed that CD4 + T cells were required during the primary immune response to HKx31 to establish rapamycin-mediated protection against a subsequent heterosubtypic infection with ∆Vn1203.
We next assessed the duration of rapamycin treatment needed to protect against infection with ∆Vn1203. We infected mice with HKx31 and treated them for 5-28 d with PBS or rapamycin. At 28 d after the primary infection, we challenged the mice with ∆Vn1203. We found that 20 d of treatment with rapamycin sufficiently protected mice from a lethal challenge with ∆Vn1203, while 5 d of treatment with rapamycin did not enhance survival ( Fig. 5d and Supplementary  Fig. 3j) ; 10 or 15 d of treatment with rapamycin provided partial protection ( Fig. 5d and Supplementary Fig. 3j ). Together these data indicated that rapamycin was required during the first 15-20 d after primary infection with HKx31 to limit the consequences of an otherwise lethal, heterosubtypic infection with ∆Vn1203 and did so by a CD4 + T cell-dependent process.
As inhibition of mTOR increases the number of regulatory T cells in vivo and in vitro 14 , rapamycin may protect against a lethal infection with ∆Vn1203 by increasing the number of regulatory T cells. However, we found no greater number or proportion of Foxp3 + CD25 + regulatory T cells in rapamycin-treated mice than in PBS-treated mice initially after the primary infection with HKx31 ( Supplementary  Fig. 6a,b) . Indeed, the proportion and number of regulatory T cells in the blood 26 d after the primary infection was slightly lower in rapamycin-treated mice than in their PBS-treated counterparts (Supplementary Fig. 6c,d) . Furthermore, the proportion and number of regulatory T cells in the spleen, bronchoalveolar lavage fluid and draining lymph nodes 5 d after the secondary infection was similar in rapamycin-and PBS-treated mice (Supplementary Fig. 6e,f) , which suggested that protection against a lethal, heterosubtypic influenza infection did not require an increase in regulatory T cells.
Protection requires B cells
The finding that rapamycin was required during the first 15 d after primary infection yet provided protection 28 d later in a CD4 + T cell-dependent manner suggested that rapamycin may have limited the secondary infection by altering the antibody response. If this were true, treatment with rapamycin during the primary infection should provide lasting protection beyond 28 d. To explore that possibility, we infected mice with HKx31, treated them daily for 28 d with PBS or rapamycin and then challenged them with ∆Vn1203 6 weeks later. A significantly greater proportion of rapamycin-treated mice than PBStreated mice survived the secondary infection despite the 6-week lag between rapamycin treatment and secondary infection ( Fig. 6a and  Supplementary Fig. 3k ), which suggested that rapamycin provided durable protection. Next, to determine whether rapamycin provided protection by altering the generation of antibodies, we infected wildtype or B cell-deficient (µMT) mice with HKx31, treated the mice with PBS or rapamycin and challenged them with ∆Vn1203. We found that rapamycin did not protect µMT mice from a secondary infection with ∆Vn1203 (Fig. 6b) , which established that B cells were required for this antigen-dependent, rapamycin-mediated protection. Furthermore, if rapamycin protected against a lethal infection with ∆Vn1203 by modulating the antibody response during primary infection with HKx31, then antibodies generated during priming with HKx31 in the presence of rapamycin should transfer protection to naive mice challenged with the lethal dose of ∆Vn1203. Thus, we obtained serum from mice infected with HKx31 and treated with PBS or rapamycin, then transferred the serum into naive µMT mice 1 d before infecting those mice intranasally with ∆Vn1203. Control mice received serum from naive mice or mice previously infected with ∆Vn1203. Notably, similar to mice given serum from ∆Vn1203-infected mice, mice that received serum from HKx31-infected, rapamycin-treated mice were protected from a lethal infection with ∆Vn1203, while mice that received serum from naive mice or HKx31-infected, PBS-treated mice were not protected ( Fig. 6c and Supplementary Fig. 3l ). These data suggested that npg rapamycin treatment protected against heterosubtypic infection with influenza virus by altering the antibody repertoire generated during the primary infection.
Rapamycin reduces class switching and germinal centers
To determine how rapamycin alters antibody synthesis during infection with influenza virus, we analyzed the serum from rapamycin-or PBS-treated, HKx31-infected mice by standard hemagglutinationinhibition (HI) and virus-microneutralization assays. The HI assay measures the ability of serum antibodies to neutralize virus by inhibiting the interaction between HA protein of influenza virus and the sialic acid receptor on red blood cells 28 . The HI titer against HKx31 did not differ significantly in mice treated with rapamycin versus those treated with PBS, and it was negligible against ∆Vn1203 for both groups ( Table 1) . The virus-microneutralization assay is more sensitive than the HI assay and is generally thought to reflect the ability of antibodies to inhibit viral entry and replication. Again, the neutralization titers for HKx31 were similar for both groups ( Table 1 ).
In addition, we detected weak neutralization of ∆Vn1203 in serum from either PBS-or rapamycin-treated mice, although this was only apparent at very high concentrations and was similar for both groups ( Table 1) . Even so, although we did not detect substantial amounts of neutralizing antibody specific for ∆Vn1203, other data indicate that non-neutralizing antibodies that bind to internal and external influenza virus epitopes may also provide protection during infection with influenza virus 13 . To probe that possibility, we next measured titers of antibodies directed against epitopes of HKx31 or ∆Vn1203 by enzyme-linked immunosorbent assay (ELISA); we used whole virus bound to plates to give access to both external and internal viral epitopes. Unexpectedly, the concentration of HKx31-specific IgM was significantly higher, while HKx31-specific IgG was moderately lower, in rapamycin-treated mice than in their PBS-treated counterparts (Fig. 7a,b) . As expected, cross-reactive antibodies that bound ∆Vn1203 epitopes in both groups of mice were not as prevalent as those specific for HKx31 epitopes (Fig. 7b,c) , and the amount of IgM cross-reactive with ∆Vn1203 epitopes was below the limit of detection by ELISA (data not shown). While the total amount of IgG specific for ∆Vn1203 epitopes did not differ between the groups (Fig. 7c) , the IgG concentrations were close to the limit of detection. The higher concentration of influenza virus-specific IgM and lower concentration of IgG in rapamycin-treated mice (Fig. 7a) suggested that rapamycin may have altered the antibody repertoire by inhibiting antibody class switching. Consequently, we measured various classes of antibodies present in the serum of mice 28 d after infection with the HKx31 with and without treatment with rapmycin. In PBStreated mice, infection with HKx31 increased the concentration of serum IgM, IgG1, and IgG2b relative to that of naive, uninfected control mice (Fig. 8a) . However, only IgM increased in the rapamycintreated mice (Fig. 8a) . These data supported the observation that treatment with rapamycin did not prevent the generation of Antibody class switching involves the proliferation of B cells and the formation of germinal centers (GCs) after exposure to antigen 29 . Thus, we next investigated whether rapamycin inhibited the formation of GCs induced by infection with HKx31. When analyzed 15 d after priming with HKx31, the proportion and number of GC (GL7 + ) B cells in the mediastinal lymph nodes that drained the peritoneal cavity were significantly lower in rapamycin-treated mice than in their PBS-treated counterparts ( Fig. 8b and Supplementary Fig. 7a) . Moreover, staining of sections with antibody to the transcriptional repressor Bcl-6 and with peanut agglutinin established that GCs were indeed absent from the mediastinal lymph nodes of the rapamycintreated mice (Fig. 8c,d and data not shown). In the spleen, the number of GCs was not different in HKx31-infected or naive mice treated with either rapamycin or PBS (Supplementary Fig. 7b ). These data indicated that rapamycin inhibited the formation of GCs in the draining lymph nodes after primary infection with HKx31.
To determine whether B cell proliferation was blocked by the dose of rapamycin used in these experiments, we quantified B cells that incorporated the thymidine analog BrdU during a 4-hour pulse. Fewer BrdU + B cells were present in the lymph nodes of rapamycin-treated mice than in those of their PBS-treated counterparts at 15 d after infection with HKx31 ( Fig. 8e and Supplementary Fig. 7c) . However, that dose of rapamycin did not completely block B cell proliferation in the lymph nodes, as shown by the similar proportion of GL7 + cells that incorporated BrdU in rapamycin-or PBS-treated mice ( Supplementary  Fig. 7e ). In the spleen, the number of BrdU + cells was significantly lower at day 20, as was the proportion of GL7 + B cells that incorporated BrdU, in rapamycin-treated mice than in PBS-treated mice ( Supplementary  Fig. 7d,f) . These data suggested that rapamycin modified antibody generation by limiting the proliferation of B cells and formation of GCs.
Rapamycin inhibits class switching independently of proliferation
To determine whether rapamycin inhibited antibody class switching by decreasing proliferation or by directly preventing antibody class switching, we used an in vitro assay to establish a dose of rapamycin low enough to not inhibit B cell proliferation, which allowed us to analyze class switching independently of proliferation (Fig. 9a,b) . We stimulated B cells for 4 d with lipopolysaccharide (LPS) alone or with LPS and interleukin 4 (IL-4), together with increasing amounts of rapamycin. The generation of IgG2b + and IgG3 + B cells in response to LPS was inhibited by rapamycin at a dose of 0.5 ng/ml, although proliferation was intact (Fig. 9a-d) . Likewise, in response to LPS and IL-4, the number of IgG1 + and IgE + B cells was lower in the presence of rapamycin than in its absence (Fig. 9e,f) . In response to LPS alone or the combination of LPS and IL-4, rapamycin increased the number of IgM + B cells (Fig. 9g) , which demonstrated that rapamycin did not diminish B cell survival but instead inhibited the switch from IgM to the other antibody classes. 
npg
We next analyzed induction of Aicda, which encodes the cytidine deaminase AID, 24 h after stimulation with LPS and IL-4, a time before proliferation was affected by rapamycin (Fig. 9h) , to confirm that the defect in class switching in the presence of rapamycin was not due to inhibition of proliferation. AID is absolutely required for class switching 30 . As mTOR functions in two distinct signaling complexes, mTORC1 and mTORC2 (ref. 14), we also assessed Aicda induction in B cells with inducible deletion of the gene encoding raptor (Rptor), an essential protein in the mTORC1 complex. Those B cells were from mice that undergo deletion of loxP-flanked Rptor alleles by a fusion of Cre recombinase and a tamoxifen-sensitive variant of the estrogen receptor expressed from the ubiquitous Rosa26 locus (called 'raptordeficient mice' here). For these studies we also used raptor-sufficient mice that express wild-type Rptor alleles plus that Rosa26-driven fusion of Cre and tamoxifen-sensitive estrogen receptor. We gave the raptor-sufficient and raptor-deficient mice intraperitoneal injection of tamoxifen daily for 4 consecutive days. Then, 8 d after the final injection, we harvested IgM + B cells from the spleen and stimulated them in vitro for 24 h with LPS and IL-4 with or without rapamycin. The number of raptor-sufficient and raptor-deficient B cells was similar (Fig. 9i) , which suggested similar proliferation at this time. Notably, Aicda mRNA increased significantly by 24 h in raptorsufficient B cells but not in raptor-deficient B cells or in rapamycintreated B cells (Fig. 9j) . These results indicated that mTORC1, in particular, was required for Aicda transcription and subsequent class switching. Moreover, we observed the requirement for mTORC1 before proliferation and it was not simply a consequence of diminished cell division. Together these data showed that mTOR was important for class switching in B cells and GC formation and that inhibiting this pathway with rapamycin during primary infection with influenza virus altered antibody generation by preventing class switching.
Rapamycin alters the antibody repertoire specificity While the concentration of IgM specific for HKx31 was higher in rapamycin-treated mice, the titer of IgG specific for HKx31 or ∆Vn1203 was not substantially different in the PBS-and rapamycintreated groups (Fig. 7) . However, the ELISA approach does not measure the amount of antibody specific for each epitope. A different approach is needed to determine whether rapamycin changes the antibody repertoire by modifying the frequency of antibodies specific for particular epitopes. To obtain a sample 'footprint' of the overall immunoglobulin response during a primary infection, we evaluated the prevalence of antibodies specific for the HA proteins of HKx31 and ∆Vn1203. We generated antigen microarrays with peptides spanning those HA proteins; these peptides were 20 amino acids in length, with an overlap of 15 amino acids to provide dense coverage of potential epitopes. We infected mice with HKx31 and treated them for 20 d with PBS or rapamycin, then obtained serum from the mice, incubated the serum on the microarrays and quantified IgG or IgM bound to each epitope by measuring the fluorescence intensity of bound antibodies to mouse IgM or IgG. The greater sensitivity of this assay than of the ELISA allowed us to analyze both IgM and IgG specific for the HA proteins of HKx31 and ∆Vn1203. We first assessed the overall response patterns of antibodies to HA of ∆Vn1203. Notably, the response patterns of both IgM (Fig. 10a) and IgG (Fig. 10b) clustered separately into two distinct groups depending on rapamycin treatment. This suggested that treatment with rapamycin induced a unique antibody signature.
We then identified the specific antigens for which the responses of the two groups differed significantly, focusing only on those antigens for which the overall response rates were greater than 20%. For each of those probes, we used Fisher's exact test to assess the number of responding mice in each of the two groups and made separate analyses npg of HKx31-specific IgM (Fig. 10c) , HKx31-specific IgG, (Fig. 10d) , ∆Vn1203-specific IgM (Fig. 10e) and ∆Vn1203-specific IgG (Fig. 10f) and presented the antigen sets with statistically significant differences in PBS-treated mice versus rapamycin-treated mice. In general, we found more diversity between the groups for IgM antibodies than for IgG antibodies specific for each viral strain. This may have been because the IgM repertoire is generally more diverse than the IgG repertoire. Analysis of antibodies specific for ∆Vn1203 established the presence of unique IgM and IgG signatures specific for particular HA epitopes in both PBS-treated mice and rapamycin-treated mice (Fig. 10e,f) . These data showed that rapamycin altered the repertoire of antibodies specific for HA glycoproteins of influenza A virus.
We next investigated the location of the peptides that yielded different responses in PBS-and rapamycin-treated mice to the HA proteins of HKx31 and ∆Vn1203. The solved structure of HKx31 HA did not include the most carboxy-terminal portion of the protein; therefore, the peptide with a start position of 551 (Fig. 10c,d) is not on the structure. Nevertheless, this analysis indicated that antibody responses to several epitopes on HA from HKx31 were present in PBS-treated mice but were absent from their rapamycin-treated counterparts (Fig. 10g) , which suggested that rapamycin decreased the overall HA-specific antibody response in the primary infection. Furthermore, the HA peptides of ∆Vn1203 that were bound by antibodies from rapamycintreated mice but not those from PBS-treated mice were located on the exterior portion of the HA of ∆Vn1203 (Fig. 10h) , which indicated that they may be accessible on the surface of the intact virus or virusinfected cell.
To further investigate the accessibility of those peptides, we computed solvent-accessible surface areas using both a water-sized probe (1.4Å) and a larger probe (4Å) that would better mimic accessibility to antibodies. We found that all the peptides that induced an antibody response exclusively in the rapamycin-treated mice were surface accessible, unlike some of the specificities that were different in the PBS-treated mice (Supplementary Table 1) . Moreover, two of the peptides identified in the rapapmycin-treated mice were previously described antibody contact sites. Notably, one of the peptides unique to the rapamycin-treated set (Fig. 10f, start position 16 ) bound an epitope in the stem region of the HA protein of ∆Vn1203, which is typically more conserved between different subtypes of HA and could thus provide protection against multiple influenza subtypes. In summary, this analysis has shown that rapamycin decreased the dominant antibody response to the HA of the vaccine strain, which in turn allowed antibodies specific for more conserved epitopes to become more prevalent. Together our data suggest that in addition to altering antibody class profiles, rapamycin changes the antibody repertoire after vaccination, which can lead to enhanced protection against a lethal heterosubtypic infection.
DISCUSSION
Here we described a model in which treatment with rapamycin enhanced protection against lethal infection with ∆Vn1203 after vaccination with the relatively avirulent HKx31. We took advantage of this system to investigate the components of the immune response that boost that cross-strain protection and made several discoveries. Most notably, a broader antibody response, rather than a highly selected and affinity-matured repertoire, enhanced heterosubtypic immunity. The protective response was promoted by the use of rapapmycin to inhibit mTOR and reduce GC formation and immunoglobulin class switching during primary infection. Also notably, the resultant altered antibody repertoire protected naive mice against lethal, heterosubtypic infection with influenza A virus.
Rapamycin modified the antibody repertoire in two ways. First, it decreased antibody class switching and thereby increased the prevalence of influenza virus-specific IgM antibodies. Although crossreactive, ∆Vn1203-specific IgM antibodies were not measurable, the finding that total IgG concentrations, but not IgM concentrations, were lower in rapamycin-treated mice than in their PBS-treated counterparts indicated that the ratio of IgM to IgG was greater in rapamycintreated mice than in PBS-treated mice. Perhaps the pentameric IgM complexes enhance low-affinity binding by increasing the avidity for a particular epitope. As antibodies specific for the conserved epitopes may bind with a lower affinity than those that bind the highly divergent HA epitopes, such enhanced avidity may be necessary for these cross-reactive antibodies to be effective 13 . Furthermore, IgM can directly activate the complement pathway to enhance protection by accelerating the clearance of viral particles and infected cells. Second, rapamycin altered the frequency of antibodies specific for particular influenza virus epitopes. This may have steered the immune response away from strain-specific responses to more cross-reactive responses. Although our antibody analysis probably underestimated the true diversity, given that the antigen arrays measured only the antibody response to HA and may not have detected antibodies that bind tertiary protein conformations, we found that rapamycin modified the binding spectrum for antibodies generated during primary infection. If such altered specificities indeed provide protection, they offer possible strategies for the development of therapeutics to protect people in the event of a deadly pandemic.
How might such cross-reactive antibodies enhance viral clearance? Rapamycin did not increase measurable titers of neutralizing antibody in serum of mice infected with HKx31, which indicated that the cross-reactive antibodies protected by a means other than preventing the entry of virus into host cells or fusion of the virus to the cell membrane. However, it is also possible that the assays available are not sensitive enough to measure weakly binding antibodies or may lack other components of the immune system, such as complement, that operate in the whole animal. Other studies have demonstrated protection by cross-reactive influenza virus-specific antibodies that do not neutralize virus in vitro 13 . Antibodies can facilitate complement-mediated clearance of viral particles or infected cells 31, 32 , Fc receptor-mediated phagocytosis of viral particles 33 and antibodydependent cell-mediated cytotoxicity 11, 34, 35 . In addition, antibodyantigen complexes can activate dendritic cells to enhance antigen presentation and chemokine production 36 .
Rapamycin disrupted the formation of GCs, which may in turn have altered the antibody repertoire. During an immune response, antibodies undergo class switching and affinity maturation in the GCs 29 . Over time, isotype-switched B cells that produce antibodies of the highest affinity are selected for 'preferential' population expansion. For infection with influenza virus, most of those high-affinity antibodies are specific for the globular head of the HA protein 13 . While those isotype-switched, affinity-matured antibodies provide the necessary protection to prevent reinfection with homologous strains, they may outcompete the antibodies of lower affinity that are specific for epitopes conserved across different influenza virus subtypes. Our data suggested that rapamycin blocked the formation of GCs and high-affinity antibodies. Consequently, antibodies of lower affinity with a greater potential to be cross-reactive were not outcompeted and therefore became more prevalent.
Our data also showed that mTOR had a critical role in the formation of GCs and antibody class switching. As B cell proliferation, GC formation and antibody class switching are so intimately linked, it is difficult to say definitively at which stage mTOR is required. npg Clearly, mTOR is needed for B cell proliferation both in vitro and in vivo 37 . However, our data indicated that at a low dose of rapamycin, which did not block proliferation, antibody class switching and the induction of Aicda were inhibited, which indicated that mTOR was critical for class switching independently of proliferation. Moreover, rapamycin and deletion of Rptor inhibited the induction of Aicda within 24 h of stimulation, yet proliferation was similar in rapamycinand PBS-treated samples.
In addition, rapamycin may impede GC formation by blocking the survival of GC B cells. GC B cells are highly susceptible to apoptosis and are therefore dependent on mTOR-induced antiapoptotic proteins, such as Mcl-1, for survival 29 . Another likely mTOR-dependent step is the migration of B cells and T cells to chemokines that are important for establishing the GCs. The chemokine receptor CXCR4 on B cells is required for GC formation, and migration to its ligand CXCL12 (SDF-1) is dependent on mTOR 38, 39 . On the basis of those data and our findings, we propose that rapamycin blocks the proliferation, survival and migration of B cells, all of which contribute to the absence of GCs in rapamycin-treated mice.
Follicular helper T cells have an essential role in GC formation and the selection of affinity-matured antibodies 40 . Our data do not exclude the possibility that rapamycin alters CD4 + follicular helper T cells or dendritic cells, which in turn affects GC formation. In fact, we did find fewer follicular helper T cells in rapamycin-treated, HKx31-infected mice than in their PBS-treated, HKx31-infected counterparts (data not shown). However, the fact that deletion of raptor in B cells or rapamycin treatment in vitro blocked the induction of Aicda transcription, B cell proliferation and antibody class-switching in a B cell-intrinsic manner indicated that mTORC1 had a critical direct role in B cells by regulating proliferation and antibody class switching. In addition, CD4 + T cells were required for the rapamycin-mediated protection, but GCs were absent, which indicated that CD4 + T cells had other necessary roles in antibody formation, including activating the B cells or cytokine secretion.
Overall, our data have demonstrated that mTORC1 was required for class switching in B cells and GC formation. Inhibition of that pathway during vaccination with influenza virus promoted a unique antibody repertoire, which enhanced heterosubtypic immunity to infection with influenza virus; this has important implications for the identification of additional cross-reactive antibodies. Moreover, this approach could be extended to the design of vaccines against other viruses that would benefit from cross-reactive antibodies, such as HIV.
METHODS
Methods and any associated references are available in the online version of the paper. 
